Description
Bid polyclonal Antibody | BS90135 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human
Application: WB ICC/IF IHC FC IP
Application Range: WB:1:500-1:1,000 ICC:1:50-1:200 IHC:1:50-1:200 FC:1:50-1:100 IP:1:10-1:50
Background: Members of the Bcl-2 family of proteins interact to regulate programmed cell death, or apoptosis. Various homodimers and heterodimers formed by proteins in this family can either promote or inhibit apoptosis. Bcl-2 blocks cell death following a variety of stimuli and confers a death-sparing effect on certain hematopoietic cell lines following growth factor withdrawal. Additional apoptotic inhibitors in this family include A1, Bag-1, Bcl-w, Bcl-x and Mcl-1. Pro-apoptotic members of this family include Bax, Bad, Bak, Bik (NBK) and BID. BID contains a BH3 domain which allows it to dimerize with and counter the death repressor effects of Bcl-2. BID has also been shown to heterodimerize with Bcl-x and the death agonist Bax. BID is localized predominantly in the cytosol and is also present in membrane fractions. It is highly expressed in kidney and can also be detected in brain, spleen, liver, testis and lung.
Storage & Stability: Store at +4°C after thawing. Aliquot store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Specificity: Bid polyclonal Antibody detects endogenous levels of Bid protein.
Molecular Weight: 22 kDa
Note: For research use only, not for use in diagnostic procedure.
Alternative Names: BID, Apoptic death agonist, Apoptotic death agonist BID, BH3 interacting domain death agonist, BH3 interacting domain death agonist p11, BH3 interacting domain death agonist p13, BH3 interacting domain death agonist p15, BH3-interacting domain death agonist p11, BID, BID isoform ES (1b), BID isoform L (2), BID isoform Si6, BID, Desmocollin type 4, FP497, Human BID coding sequence, MGC15319, MGC42355, p11 BID, p13 BID, p15 BID, p22 BID,
Immunogen: recombinant protein
Conjugate: Unconjugated
Modification: Unmodification
Purification & Purity: ProA affinity purified
Pathway: